The Competition Appeal Tribunal upheld the CMA’s finding on Thursday, February 25, that Lexon broke competition law and dismissed Lexon’s appeal.
Last year, the Competition and Markets Authority (CMA) concluded its investigation into the supply of nortriptyline, a drug relied on by thousands of patients daily to relieve symptoms of depression.
The CMA found that pharmaceutical firm Lexon, along with King Pharmaceuticals and Alissa Healthcare Research, had illegally shared commercially sensitive information to try to keep nortriptyline prices up. From 2015 to 2017, when the cost of the drug was falling, the 3 suppliers exchanged information about prices, the volumes they were supplying, and Alissa’s plans to enter the market.
As a result, the CMA fined all 3 companies, fining Lexon a total of £1,220,383 (US$1,7 million). Lexon maintained that it had not broken the law and so appealed against the decision and the fine.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canada Investigates Major Grocers for Anticompetitive Practices
May 26, 2024 by
CPI
John Hess Scrambles to Secure Shareholder Approval for $53 Billion Chevron Merger
May 26, 2024 by
CPI
Petrobras Retains Refineries and Gas Pipeline in CADE’s Landmark Reversal
May 26, 2024 by
CPI
Meta Proposes New Data Limits on Facebook Marketplace in UK Amid CMA Oversight
May 26, 2024 by
CPI
EU Industry Chief Calls for Unified Tech Regulations Between US and Europe
May 26, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI